The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone

Sid P Kerkar, Clinton D Kemp, Austin Duffy, Udai S Kammula, David S Schrump, King F Kwong, Martha Quezado, Barry R Goldspiel, Aradhana Venkatesan, Ann Berger, Melissa Walker, Mary Ann Toomey, Seth M Steinberg, Guiseppe Giaccone, Steven A Rosenberg, Itzhak Avital, Sid P Kerkar, Clinton D Kemp, Austin Duffy, Udai S Kammula, David S Schrump, King F Kwong, Martha Quezado, Barry R Goldspiel, Aradhana Venkatesan, Ann Berger, Melissa Walker, Mary Ann Toomey, Seth M Steinberg, Guiseppe Giaccone, Steven A Rosenberg, Itzhak Avital

Abstract

Background: The standard of care for metastatic gastric cancer (MGC) is systemic chemotherapy which leads to a median survival of 6-15 months. Survival beyond 3 years is rare. For selected groups of patients with limited MGC, retrospective studies have shown improved overall survival following gastrectomy and metastasectomies including peritoneal stripping with continuous hyperthermic peritoneal perfusion (CHPP), liver resection, and pulmonary resection. Median survival after liver resection for MGC is up to 34 months, with a five year survival rate of 24.5%. Similarly, reported median survival after pulmonary resection of MGC is 21 months with long term survival of greater than 5 years a possibility. Several case reports and small studies have documented evidence of long-term survival in select individuals who undergo CHPP for MGC.

Design: The GYMSSA trial is a prospective randomized trial for patients with MGC. It is designed to compare two therapeutic approaches: gastrectomy with metastasectomy plus systemic chemotherapy (GYMS) versus systemic chemotherapy alone (SA). Systemic therapy will be composed of the FOLFOXIRI regimen. The aim of the study is to evaluate overall survival and potential selection criteria to determine those patients who may benefit from surgery plus systemic therapy. The study will be conducted by the Surgery Branch at the National Cancer Institute (NCI), National Institutes of Health (NIH) in Bethesda, Maryland. Surgeries and followup will be done at the NCI, and chemotherapy will be given by either the local oncologist or the medical oncology branch at NCI.

Trial registration: ClinicalTrials.gov ID. NCT00941655.

Figures

Figure 1
Figure 1
Trial Schema.

References

    1. Globocan 2002 database.
    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun M. Cancer Statistics 2008. CA Cancer J Clin. 2008;58:71–96. doi: 10.3322/CA.2007.0010.
    1. Sakamoto Y, Ohyama S, Yamamoto J, Yamada K, Seki M, Ohta K, Kokudo Yamaguchi T, Muto T, Makuuchi M. Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery. 2003;133:507–511. doi: 10.1067/msy.2003.147.
    1. Okano K, Takashi M, Ishimura K, Karasawa Y, Goda F, Wakabayashi H, Usuki H, Maeta H. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg. 2001;235:86–91. doi: 10.1097/00000658-200201000-00011.
    1. Zacherl J, Zacherl M, Scheuba C, Steininger R, Wenzl E, Muhlbacher F, Jakesz R, Friedrich L. Analysis of hepatic resection of metastasis originating from gastric adenocarcinoma. J Gastrointest Surg. 2002;6:682–689. doi: 10.1016/S1091-255X(01)00075-0.
    1. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluorouracil epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71:58–591.
    1. Murad AM, Santiago FF, Petroianu A, Rodrigues MAG, Rauch M. Modified therapy with 5 fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72:37–41. doi: 10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>;2-P.
    1. Leong T. Evolving Chemotherapy for advanced gastric cancer. Oncologist. 2005;21:673–678.
    1. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van Cutsem E. V-325 Study Group: Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007;25(22):3205–3209. doi: 10.1200/JCO.2006.10.4968.
    1. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15(1):261–267.
    1. Lee J, Kang WK, Kwon JM, Oh SY, Lee HR, Kim HJ, Park BB, Lim HY, Han MJ, Park JO, Park YS. Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinomas. Ann Oncol. 2007;18(1):88–92. doi: 10.1093/annonc/mdl317.
    1. Cao W, Yang W, Lou G, Jiang J, Geng M, Xi W, Li H, Ma T, Jin Y. Phase II trial of infusion fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer. Anticancer Drugs. 2009;20(4):287–293. doi: 10.1097/CAD.0b013e3283273509.
    1. Yonemura Y, Fujimura T, Nishimura G, Falla R, Sawa T, Katayama K, Tsugawa K, Fushida S, Miyazaki I, Tanaka M, Endou Y, Sasaki T. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery. 1996;119:437–444. doi: 10.1016/S0039-6060(96)80145-0.
    1. Fujimoto S, Shrestha RD, Kokubun M, Kobayashi K, Kiuchi S, Konno C, Okui K. Clinical outcome of combined therapy on intraoperative hyperthermochemotherapy and surgery for patients with peritoneal recurrence from gastric cancer. Reg Cancer Treat. 1990;3:181–184.
    1. Hirose K, Katayama K, Iida A, Yamaguchi A, Nakagawara G, Umeda S, Kusaka Y. Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis. Oncology. 1999;57:106–114. doi: 10.1159/000012016.
    1. Yoo CH. Early postoperative intraperitoneal chemotherapy(EPIC) for advanced gastric cancer. Proceedings of the 3rd International Gastric Cancer Congress: 27-30 April 1999; Seoul, Korea. p. 103.
    1. Kanemitsu Y, Kondo H, Katai H, Nakayama H, Asamura H, Tsuchiya R, Naruke T. Surgical resection of pulmonary metastases from gastric cancer. J Surg Oncol. 1998;69:147–150. doi: 10.1002/(SICI)1096-9098(199811)69:3<147::AID-JSO5>;2-H.
    1. Tamura M, Hiroshima K, Sugita K, Kobayashi S, Miyoshi S. Four cases of resected pulmonary tumor metastastic from gastric cancer. Japanese Journal of Lung Cancer. 2002;42(6):611–613.
    1. Tsumatori G, Ozeki Y, Aoki T, Watanabe M, Tanaka S, Aida S. Five cases of surgically resected pulmonary metastases from gastric cancer: relationship between the expression of carbohydrate antigen and metastasis. Jpn J Chest Surg. 1998;12:85–91.
    1. Inoue Y, Kido T, Tanaka Y, Ogawa T, Yamamoto S. A long-term survivor after early gastric cancer with two times of lung metastases which were successfully resected. Nippon Rinshogeka Gakkai Zasshi. 2002;63:52–55.
    1. Nakahashi C, Kinoshita T, Konishi M, Nakagohri T, Inoue K, Oda T, Yoshida J, Hasebe T, Ochiai A. Long term survival achieved by repeated resections of metachronous pulmonary and adrenal metastases of alpha-fetoprotein producing gastric cancer: report of a case. Surgery Today. 2004;34:784–787. doi: 10.1007/s00595-004-2796-3.
    1. Sakaguchi K, Yamamoto M, Horio H. Resection of solitary pulmonary metastasis from gastric cancer. Jpn J of Lung Ca. 2007;47(4):323–326. doi: 10.2482/haigan.47.323.
    1. Cunningham D, Rao D, Starling N. Randomised multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL-2 trial [Abstract] J Clin Oncol. 2006;24:182s.
    1. Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM, Ferraldeschi R, Naso G, Filipponi F, Pietrabissa A, Goletti O, Baldi G, Fornaro L, Andreuccetti M, Falcone A. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249(3):420–425. doi: 10.1097/SLA.0b013e31819a0486.
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. JNCI. 1993;85:365–376. doi: 10.1093/jnci/85.5.365.
    1. Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, Moore J, Koller M, Turhal NS, Stuart R, Van Cutsem E, D'haese S, Coens C. European Organisation for Research and Treatment of Cancer Gastrointestinal and Quality of Life Groups. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer. 2004;40(15):2260–2268. doi: 10.1016/j.ejca.2004.05.023.
    1. Eremenco SL, Cashy J, Webster K. FACT-Gastric: A new international measure of QOL in gastric cancer [Abstract] J Clin Oncol. 2004;22:s8123.
    1. EORTC Group for research into quality of life: EORTC QLQC30.
    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun M. Cancer Statistics 2008. CA Cancer J Clin. 2008;58:71–96. doi: 10.3322/CA.2007.0010.
    1. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera C, Weber S, Blumgart LH. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg. 2002;236:397–406. doi: 10.1097/00000658-200210000-00001.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera